[go: up one dir, main page]

MX2015007185A - Uso de eribulina en el tratamiento de cancer de pecho. - Google Patents

Uso de eribulina en el tratamiento de cancer de pecho.

Info

Publication number
MX2015007185A
MX2015007185A MX2015007185A MX2015007185A MX2015007185A MX 2015007185 A MX2015007185 A MX 2015007185A MX 2015007185 A MX2015007185 A MX 2015007185A MX 2015007185 A MX2015007185 A MX 2015007185A MX 2015007185 A MX2015007185 A MX 2015007185A
Authority
MX
Mexico
Prior art keywords
breast cancer
eribulin
treatment
subjects
provides methods
Prior art date
Application number
MX2015007185A
Other languages
English (en)
Inventor
He Yi
Kremer Alton
Tarassoff Peter
Olivo Martin
Matthew Guo D
Savulsky Claudio
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50031376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015007185(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2015007185A publication Critical patent/MX2015007185A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención provee métodos de tratar cáncer de pecho en sujetos que tienen cáncer de pecho diseminado localmente o metastásico.
MX2015007185A 2012-12-04 2013-12-04 Uso de eribulina en el tratamiento de cancer de pecho. MX2015007185A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261733238P 2012-12-04 2012-12-04
US201361878204P 2013-09-16 2013-09-16
PCT/IB2013/002911 WO2014087230A1 (en) 2012-12-04 2013-12-04 Use of eribulin in the treatment of breast cancer

Publications (1)

Publication Number Publication Date
MX2015007185A true MX2015007185A (es) 2017-09-05

Family

ID=50031376

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015007185A MX2015007185A (es) 2012-12-04 2013-12-04 Uso de eribulina en el tratamiento de cancer de pecho.

Country Status (11)

Country Link
US (1) US20140163095A1 (es)
EP (1) EP2928464A1 (es)
JP (2) JP6466339B2 (es)
KR (1) KR20150090921A (es)
AU (2) AU2013353745A1 (es)
BR (1) BR112015012731A2 (es)
CA (1) CA2892780A1 (es)
IL (1) IL239007B (es)
MX (1) MX2015007185A (es)
RU (1) RU2689977C2 (es)
WO (1) WO2014087230A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS54054B1 (sr) 2004-06-03 2015-10-30 Eisai R&D Management Co. Ltd. Intermedijeri za pripremu halihondrina b
DK2415470T3 (en) 2009-03-30 2016-09-19 Eisai R&D Man Co Ltd liposome
AU2010285740C1 (en) 2009-08-19 2016-03-17 Eisai R&D Management Co., Ltd. Quinoline derivative-containing pharmaceutical composition
EP3444363B1 (en) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
KR20150090921A (ko) * 2012-12-04 2015-08-06 에자이 알앤드디 매니지먼트 가부시키가이샤 유방암 치료에서 에리불린의 용도
JP6644479B2 (ja) * 2014-06-24 2020-02-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 がん治療のための併用療法としてのエリブリンとｓ−１（もしくは５−ｆｕ）の使用
JP6659554B2 (ja) 2014-08-28 2020-03-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 高純度キノリン誘導体およびその製造方法
LT3263106T (lt) 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. Chinolino darinių kartumo sumažinimo būdas
KR20170122810A (ko) 2015-03-04 2017-11-06 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 에리불린의 조합
AU2016279474B2 (en) 2015-06-16 2021-09-09 Eisai R&D Management Co., Ltd. Anticancer agent
SG11201801083UA (en) 2015-08-20 2018-03-28 Eisai R&D Man Co Ltd Tumor therapeutic agent
WO2017188350A1 (ja) 2016-04-28 2017-11-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍の成長を抑制する方法
CN110072528B (zh) 2017-02-08 2022-04-26 卫材R&D管理有限公司 治疗肿瘤的药物组合物
MA47502A (fr) * 2017-02-20 2019-12-25 Polyphor Ag Combinaisons pharmaceutiques pour traiter le cancer
KR20200013644A (ko) 2017-05-16 2020-02-07 에자이 알앤드디 매니지먼트 가부시키가이샤 간세포 암종의 치료
EP3654967A4 (en) * 2017-07-21 2021-04-21 Eisai R&D Management Co., Ltd. USE OF EIBULIN AND CYCLINE-DEPENDENT KINASE INHIBITORS IN THE TREATMENT OF CANCER
EP3713565A1 (en) 2017-11-20 2020-09-30 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
WO2019152989A1 (en) * 2018-02-05 2019-08-08 Tesaro, Inc Pediatric niraparib formulations and pediatric treatment methods
CN112262157A (zh) * 2018-03-09 2021-01-22 加利福尼亚大学董事会 化药抗性癌症的组合治疗
JP2022506829A (ja) * 2018-11-09 2022-01-17 ジー１、セラピューティクス、インコーポレイテッド エリブリンと選択的ｃｄｋ４／６阻害剤との組合せを使用する癌の処置のための治療レジメン
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
WO2025106586A1 (en) * 2023-11-13 2025-05-22 Luxvitae Therapeutics Inc. Macrocyclic ketone compounds and applications thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
JP4454151B2 (ja) 1998-06-17 2010-04-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 大環状類似体及びそれらの使用並びに調製方法
RS54054B1 (sr) 2004-06-03 2015-10-30 Eisai R&D Management Co. Ltd. Intermedijeri za pripremu halihondrina b
BRPI0607809A2 (pt) * 2005-02-18 2009-06-13 Abraxis Bioscience Inc uso de uma composição compreendendo nanopartìculas, composição e kit
US8168216B2 (en) * 2006-03-22 2012-05-01 Medigene Ag Treatment of triple receptor negative breast cancer
EP2200992B1 (en) 2007-10-03 2014-02-26 Eisai R&D Management Co., Ltd. Intermediates and methods for the synthesis of halichondrin b analogs
CN102056930B (zh) 2008-04-04 2016-04-20 卫材R&D管理有限公司 软海绵素b类似物
SG182612A1 (en) 2010-01-26 2012-08-30 Eisai R&D Man Co Ltd Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs
ES2731653T3 (es) * 2011-03-18 2019-11-18 Eisai R&D Man Co Ltd Métodos y usos para predecir la respuesta a la eribulina
KR20150090921A (ko) * 2012-12-04 2015-08-06 에자이 알앤드디 매니지먼트 가부시키가이샤 유방암 치료에서 에리불린의 용도

Also Published As

Publication number Publication date
AU2018214086B2 (en) 2020-07-09
IL239007B (en) 2018-04-30
RU2015126539A (ru) 2017-01-13
KR20150090921A (ko) 2015-08-06
US20140163095A1 (en) 2014-06-12
JP2016501213A (ja) 2016-01-18
EP2928464A1 (en) 2015-10-14
BR112015012731A2 (pt) 2017-07-11
JP2019089776A (ja) 2019-06-13
AU2013353745A1 (en) 2015-06-11
JP6466339B2 (ja) 2019-02-06
CA2892780A1 (en) 2014-06-12
WO2014087230A1 (en) 2014-06-12
AU2018214086A1 (en) 2018-08-23
JP6678783B2 (ja) 2020-04-08
IL239007A0 (en) 2015-07-30
RU2689977C2 (ru) 2019-05-30

Similar Documents

Publication Publication Date Title
MX2015007185A (es) Uso de eribulina en el tratamiento de cancer de pecho.
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
HRP20220897T8 (hr) Kombinirana terapija koja uključuje antitijela protiv klaudina 18.2 za liječenje raka
PL2958945T3 (pl) Terapia skojarzona wykorzystująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu
SI3033086T1 (sl) Kombinirana terapija za zdravljenje raka
EA201400178A1 (ru) Лечение рака молочной железы
BR112014021104A2 (pt) métodos e composições para o tratamento da doença de huntington
MX2014009751A (es) Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer.
SI2766040T1 (sl) Pertuzumab, Trastuzumab, Docetaxel in Carboplatin za zdravljenje zgodnjega raka dojke
GEP20217317B (en) Combination therapy for the treatment of cancer
IL276733A (en) Use of Aribolin in cancer treatment
MX2015011899A (es) Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
EA201591925A1 (ru) Терапевтические композиции и их применение
PL3490560T3 (pl) Niraparyb do stosowania w sposobie leczenia nowotworu prostaty
UA117663C2 (uk) Антиандроген для лікування неметастатичного кастраційно-резистентного раку передміхурової залози
MX2015011518A (es) Agentes de enlace de met y usos de los mismos.
MX2016000131A (es) Nanoparticulas polimericas de docetaxel para el tratamiento de cancer.
HUE054998T2 (hu) Kombinációs terápiák emlõrák kezelésében való alkalmazásra
IL290251A (en) Combination for effective treatment of metastatic cancer in patients
ZA201708686B (en) Nanoparticles for use as a therapeutic vaccine
DK3383872T3 (da) 1,3,4-thiadiazolforbindelser og anvendelse deraf i cancerbehandling
CY1117438T1 (el) Μεθοδος για την προληψη και την θεραπευτικη αντιμετωπιση της σηψης
MX385322B (es) Uso de sedoheptulosa para la prevención y tratamiento de inflamación.
EA201590615A1 (ru) Стимулирующие лактацию композиции на основе фосфатидилсерина
MX2014012535A (es) Terapia de combinacion de anticuerpos anti-mif y quimioterapeuticos.